Literature DB >> 17722714

Successful treatment of fulminant encapsulating peritoneal sclerosis following fungal peritonitis with tamoxifen.

S Gupta1, G Woodrow.   

Abstract

Encapsulating peritoneal sclerosis remains a serious complication of peritoneal dialysis. Prolonged duration on dialysis and severe episodes of peritonitis are the two most important risk factors for developing the condition. Here we describe a patient who developed a fulminant form of encapsulating peritoneal sclerosis soon after suffering from an episode of fungal peritonitis. There was clinical evidence of ongoing inflammation and gross malnutrition. Signs of chronic intestinal stasis were present on radiological imaging. There was concern in this situation that symptoms could partly relate to ongoing peritoneal sepsis, which could be worsened by immunosuppressives such as steroids. Tamoxifen was used without steroids in our patient with prompt resolution of stasis symptoms and withdrawal of artificial nutrition support. To our knowledge tamoxifen has never been previously used alone, in this scenario. We propose that tamoxifen might be a safer alternative to use in this clinical setting where there is concern about presence of ongoing sepsis, than corticosteroids and immunosuppressive agents.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17722714     DOI: 10.5414/cnp68125

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  6 in total

Review 1.  Encapsulating peritoneal sclerosis.

Authors:  Christopher J Danford; Steven C Lin; Martin P Smith; Jacqueline L Wolf
Journal:  World J Gastroenterol       Date:  2018-07-28       Impact factor: 5.742

2.  mTOR inhibitors for medical treatment of post-transplantation encapsulating peritoneal sclerosis: a favourable single center experience.

Authors:  Maria Messina; Claudia Ariaudo; Alberto Mella; Vincenzo Cantaluppi; Giuseppe P Segoloni; Luigi Biancone
Journal:  J Nephrol       Date:  2015-01-14       Impact factor: 3.902

3.  Encapsulating peritoneal sclerosis in the new millennium: a national cohort study.

Authors:  Michaela C Brown; Keith Simpson; Jan J Kerssens; Robert A Mactier
Journal:  Clin J Am Soc Nephrol       Date:  2009-06-18       Impact factor: 8.237

4.  Apoptosis inhibitor of macrophage ameliorates fungus-induced peritoneal injury model in mice.

Authors:  Takako Tomita; Satoko Arai; Kento Kitada; Masashi Mizuno; Yasuhiro Suzuki; Fumiko Sakata; Daisuke Nakano; Emiri Hiramoto; Yoshifumi Takei; Shoichi Maruyama; Akira Nishiyama; Seiichi Matsuo; Toru Miyazaki; Yasuhiko Ito
Journal:  Sci Rep       Date:  2017-07-25       Impact factor: 4.379

5.  Vascular Endothelial Cell Injury Is an Important Factor in the Development of Encapsulating Peritoneal Sclerosis in Long-Term Peritoneal Dialysis Patients.

Authors:  Mitsuhiro Tawada; Yasuhiko Ito; Chieko Hamada; Kazuho Honda; Masashi Mizuno; Yasuhiro Suzuki; Fumiko Sakata; Takeshi Terabayashi; Yoshihisa Matsukawa; Shoichi Maruyama; Enyu Imai; Seiichi Matsuo; Yoshifumi Takei
Journal:  PLoS One       Date:  2016-04-27       Impact factor: 3.240

Review 6.  Encapsulating Peritoneal Sclerosis: Pathophysiology and Current Treatment Options.

Authors:  Rajesh M Jagirdar; Andreas Bozikas; Sotirios G Zarogiannis; Maria Bartosova; Claus Peter Schmitt; Vassilios Liakopoulos
Journal:  Int J Mol Sci       Date:  2019-11-16       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.